What This Means for Small Business Health Insurance While many big businesses are making the decision about whether to include GLP-1s for their employees on a mass scale, small businesses actually have the power to be more flexible
They are operating in a state in which choice itself has been compromised
With Color Health CEO & Co-founder Othman Laraki With Color Health CEO & Co-founder Othman Laraki Most AI in healthcare promises superintelligencebut what if thats the wrong goal entirely
Companies like Lifelabs and Dynacare offer comprehensive panels at reasonable costs across most Canadian provinces
Switching from Ozempic to retatrutide: what to know For people currently taking Ozempic who are eyeing retatrutide as a future upgrade, the transition question is natural
According to KFF analysis of Centers for Medicare & Medicaid Services 2018-2022 Medicare Part D spending by drug increased from $57 Million to $5.7 Billion.[2] The June 13, 2024 article in Fierce Healthcare[3] on GLP-1 drugs noted that Blue Cross Blue Shield of Michigan will no longer cover these drugs starting in January 2025, and will be changing the prior authorization criteria starting in August 2024, for those members that are in large group fully insured commercial plans